WAKEFIELD, Mass.--(BUSINESS WIRE)--Sept. 30, 2005--Implant Sciences Corporation (AMEX: "IMX", "IMX.WS") a developer and manufacturer of products for national security, medicine and industry, today announced the execution of an exclusive supply agreement with Elekta , an international medical-technology Group with installations at over 3,000 hospitals around the world., to supply the Company's Brachytherapy treatment planning systems to its customers. Elekta manufactures and sells non-invasive or minimally invasive radiation therapy equipment for the treatment of cancer, including prostate cancer.
During fiscal 2005, Implant Sciences purchased proprietary treatment planning technology from Rosses Medical Systems Inc. and further enhanced it into the present I-Plant(TM) TPS product. In its latest version, the Company has developed a new module which aids the physician in making 2 and 3 dimensional maps of stage, grade and location of cancer within the prostate gland. This "Pathology Mapping Module(TM)" is in addition to the standard treatment planning function used for prostate Brachytherapy and will provide for image guided, focal treatment of the disease.
Dr. Anthony J. Armini, PhD., CEO of Implant Sciences, commented, "We are pleased to make our brachytherapy treatment planning system available to Elekta as a compliment to their radiation therapy equipment. We believe this arrangement could provide Implant incremental sales of our treatment planning system, as well as provide an opportunity to convert users of competitive prostate seeds to Implant's I-Plant(TM) radioactive seed for the treatment of prostate cancer."
About Implant Sciences
Implant Sciences, incorporated in 1984, is using its core ion technology to develop, manufacture and market products for the homeland security, semiconductor and medical device industries. The Company has developed and commercialized portable and bench-top detection devices to identify explosives. In addition, to its other cancer treatment products the Company recently received an FDA 510k approval for its new radioactive source for the use in the treatment of breast cancer. For further details on the Company and its products please visit the Company's website at www.implantsciences.com.
About Elekta
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. Clinical solutions include, among others, Leksell Gamma Knife(r) for non-invasive treatment of brain surgery and Elekta Synergy(r) for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, The Elekta Group is the world's largest supplier of oncology software. Elekta's systems and solutions are used at over 3,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. With approximately 1,700 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb.
Implant Sciences believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review Implant Sciences' filings with the Securities and Exchange Commission.
CONTACT: Implant Sciences Corporation
Investor Relations
781-246-0700, ext. 105
www.implantsciences.com
SOURCE: Implant Sciences Corporation |
